RxDoctor Payments DataLook up a doctor →

Neil Gheewala, MD

Interventional Cardiology · Tucson, AZNPI 1952562647

Payments from drug & device makers

$319,277in general payments, 2019–2025

Across 557 payments — averaging $573.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$250K
  • Abbott$46K
  • Boston Scientific$18K
  • Abiomed$1K
  • Medtronic$875
  • Novartis$601
  • plus $3K from 25 others

What the payments were for

  • Consulting fees$65,91647%
  • Speaking & faculty fees$25,48818%
  • Travel & lodging$33,25724%
  • Food & beverage$15,82011%
  • Education$190%
  • Other$660%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$319,277 in reported general payments places this provider in the 90th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$372,245
Medicare patients
820
Services billed
3,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban253$326,086
EntrestoSacubitril/Valsartan101$133,275
XareltoRivaroxaban69$83,093
JardianceEmpagliflozin46$57,337
Repatha SureclickEvolocumab33$32,136
BrilintaTicagrelor23$14,983
FarxigaDapagliflozin Propanediol11$11,805
Praluent PenAlirocumab14$6,945
Repatha SyringeEvolocumab19$6,185
Atorvastatin Calcium461$4,853
Metoprolol Succinate372$4,676
Prasugrel Hcl13$3,488
Ranolazine ErRanolazine16$2,095
ClopidogrelClopidogrel Bisulfate161$2,005
Lisinopril266$1,728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$248$326,086253 claims
NovartisEntresto$601$133,275101 claims
Johnson & JohnsonXarelto$32$83,09369 claims
AstraZenecaBrilinta, Farxiga$12$26,78834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →